Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of FOLFOXIRI Plus Panitumumab as First-Line Treatment for Kras and Braf Wild-Type Metastatic Colorectal Cancer

NCT01358812 is registered in ClinicalTrials.gov with Gruppo Oncologico del Nord-Ovest as lead sponsor.

NCT NCT01358812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01358812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of FOLFOXIRI Plus Panitumumab as First-Line Treatment for Kras and Braf Wild-Type Metastatic Colorectal Cancer
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
Not reported
Enrollment
37 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colo-rectal cancer